Share your requirements to help us to customize the report.
   I acknowledge that I have read the Privacy Policy
Confidentiality

We respect your privacy rights and safeguard your personal information. We prevent the disclosure of personal information to third parties.

Analyst Support
$5,300
BUY NOW GET FREE SAMPLE

FAQs

Infectious Disease Therapeutics Market size was valued at USD 115 billion in 2019 and is poised to grow from USD 119.86 billion in 2023 to USD 166.97 billion by 2031, growing at a CAGR of 4.23% in the forecast period (2024-2031).

Global infectious disease therapeutics market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'GlaxoSmithKline plc', 'Merck & Co.', 'Pfizer Inc.', 'Roche Holding AG', 'Novartis AG', 'Sanofi S.A.', 'Johnson & Johnson', 'AstraZeneca plc', 'AbbVie Inc.', 'Amgen Inc.', 'Bristol-Myers Squibb Company', 'Eli Lilly and Company', 'Gilead Sciences, Inc.', 'Bayer AG', 'Novo Nordisk A/S', 'Takeda Pharmaceutical Co. Ltd.', 'Biogen Inc.', 'Boehringer Ingelheim GmbH', 'Allergan plc', 'Celgene Corporation'

Increased spending to enhance the penetration rate of infectious disease treatments, rising strategies to raise awareness about treatments and diagnosis of these conditions, and increased clinical trial research for the development of new drugs may drive the growth of global infectious disease therapeutics market over the forecast period.

Increasing prevalence of malaria disease in developing and underdeveloped countries including India, Africa, and other Southeast Asian countries, as well as increased research and development activities by key manufacturers and health care organisations, are all contributing to market development.

North America held the largest global infectious disease therapeutics market share in 2021 due to the region's growing rate of infectious diseases. This region's large geriatric population has emerged as a significant growth factor for the market during the forecast period. People's increased disposable income has also become an important growth factor. The government's provision of advanced health-care facilities in the form of reimbursement policies has greatly aided market growth. Moreover, the existence of key manufacturers in the United States, as well as an increase in clinical trials for the introduction of new treatment drugs, are estimated to generate to this region's large market share.

Feedback From Our Clients

Global Infectious Disease Therapeutics Market

Product ID: SQMIG35J2030

$5,300
BUY NOW GET FREE SAMPLE